Welcome to The Cardio-Renal Anaemia Syndrome Academy

Comments are closed.

New to CRAS-Academy.com

Good or bad news for anaemia management in CRAS patients?

Erythropoiesis stimulating agents (ESAs) appear to have a better safety profile in patients with heart failure compared with patients with renal disease. This is one of the issues raised by the authors of a new review paper in Nature Reviews Cardiology. What does this mean for anaemia management in patients with CRAS? Read on...